Read + Share
Taniguchi H, Akagi K, Dotsu Y, Yamada T, et al. Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation
in ALK-rearranged lung cancer. Cancer Sci 2022 Sep 10. doi: 10.1111/cas.15579.
PMID: 36086904
|
 |
|
Taniguchi H, Akagi K, Dotsu Y, Yamada T, et al. Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation
in ALK-rearranged lung cancer. Cancer Sci 2022 Sep 10. doi: 10.1111/cas.15579.
PMID: 36086904
|
|
|
|